Christopher Lieu, MD

GI Oncology Now

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Christopher Lieu, MD, of University of Colorado Medicine, details three studies of practice-changing importance to keep an eye on.
He breaks down the expanded analyses of <a href="https://www.docwirenews.com/post/checkmate-9dw-ipi-nivo-as-first-line-treatment-for-uhcc" target="_blank" rel="noopener">CheckMate-9DW</a>, BREAKWATER in BRAF V600E-mutant metastatic colorectal cancer, and the first results of nivolumab plus ipilimumab vs nivolumab monotherapy for MSI-H/dMMR metastatic colorectal cancer from CheckMate 8HW.

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Christopher Lieu, MD, of University of Colorado Medicine, details three studies of practice-changing importance to keep an eye on.He breaks down the expanded analyses of <a href="https://www.docwirenews.com/post/checkmate-9dw-ipi-nivo-as-first-line-treatment-for-uhcc" target="_blank" rel="noopener">CheckMate-9DW</a>, BREAKWATER in BRAF V600E-mutant metastatic colorectal cancer, and the first results of nivolumab plus ipilimumab vs nivolumab monotherapy for MSI-H/dMMR metastatic colorectal cancer from CheckMate 8HW.

Laura W. Goff, MD

From Frontline to Adjuvant: Dr. Laura Goff on the Expanding Role and Limits of Immunotherapy in HCC

Liver Cancer

Scott Kopetz, MD, PhD

BREAKWATER Advances: Dr. Scott Kopetz on First-Line Therapy for BRAF V600E-Mutated mCRC

Colorectal Cancer

Jessica Ganga

INTRIGUE: Final Overall Survival Analysis of Ripretinib Compared With Sunitinib in Patients With GIST

GIST

Latest News

ASCO GI Studies to Monitor

Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.